Treatment evolution and survival impact of consolidation therapies in mantle cell lymphoma: insights from an Asia-Pacific real-world registry
The study reports that upfront autologous stem cell transplantation (ASCT) was associated with significantly superior survival outcomes in patients with mantle cell lymphoma (MCL) who were eligible for ASCT based on age and response criteria.
This finding highlights that conventional consolidation therapy with ASCT remains an effective strategy for improving progression‑free and overall survival in younger patients with newly diagnosed mantle cell lymphoma, even in the era of modern targeted agents.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
- Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology
- Refining risk stratification for mantle cell lymphoma: integrating novel combination treatments and personalized approaches.
- Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Hairy Cell Leukemia: Clinical Characteristics and Outcomes from a Single Center in the Middle East and North Africa